AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk’s amycretin is a single molecule designed to bind to two targets to spark weight loss — a different approach than some of the pharma giant’s other efforts to develop next ...

Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to ...

Looking ahead, Novo Nordisk’s pipeline includes several promising candidates that could further strengthen its position in the metabolic disease space. Amycretin, a once-daily oral GLP-1/Amylin ...

Novo Nordisk has been developing next-generation therapies that combine GLP-1 with amylin. Its experimental candidates, amycretin and CagriSema, aim to improve weight loss outcomes through a dual ...

A subcutaneous version of amycretin also performed well in a phase 1b/2a study. Novo Nordisk seems to have a GLP-1 medicine development engine that grants it an edge against almost any other ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.